Predictors of drug survival for tumour necrosis factor-α and interleukin 12/23 antagonists in psoriasis
- PMID: 27535601
- DOI: 10.1111/bjd.14612
Predictors of drug survival for tumour necrosis factor-α and interleukin 12/23 antagonists in psoriasis
Comment on
-
Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.Br J Dermatol. 2016 Aug;175(2):340-7. doi: 10.1111/bjd.14552. Epub 2016 Jun 25. Br J Dermatol. 2016. PMID: 26989852
Similar articles
-
Data on the safety of psoriasis therapies.Semin Cutan Med Surg. 2014 Jun;33(4 Suppl):S73-5. doi: 10.12788/j.sder.0099. Semin Cutan Med Surg. 2014. PMID: 25268600
-
When anti-TNF fails, anti-IL12-23 is an alternate option in psoriasis and psoriatic arthritis.Rev Bras Reumatol. 2014 May-Jun;54(3):247-9. Rev Bras Reumatol. 2014. PMID: 25054605 English, Portuguese.
-
Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells.Arthritis Rheum. 2010 Feb;62(2):430-40. doi: 10.1002/art.27203. Arthritis Rheum. 2010. PMID: 20112373
-
Prospective new biologic therapies for psoriasis and psoriatic arthritis.J Drugs Dermatol. 2010 Aug;9(8):947-58. J Drugs Dermatol. 2010. PMID: 20684145 Review.
-
Safety of biologics in psoriasis.J Dermatol. 2018 Mar;45(3):279-286. doi: 10.1111/1346-8138.14096. Epub 2017 Dec 10. J Dermatol. 2018. PMID: 29226369 Review.
Cited by
-
Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis.Int J Mol Sci. 2023 May 12;24(10):8703. doi: 10.3390/ijms24108703. Int J Mol Sci. 2023. PMID: 37240048 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources